Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20375384 | 0.90 | GLP1R (0.41) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL20375516 | 0.89 | GLP1R (0.41) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL23714586 | 0.89 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL20800932 | 0.88 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL23714560 | 0.88 | GLP1R (0.40) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL24479569 | 0.87 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL18715377 | 0.87 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL18715404 | 0.87 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL22566683 | 0.87 | GLP1R (0.39) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL21287423 | 0.86 | GLP1R (0.42) | GLP1RPOLBPLGPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238602-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238602-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | TEK, PLIN3, PNLIP | GLP1R 459/4885POLB 3864/4885PLG 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.